Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Study Overview: Bristol-Myers Squibb recently completed a study titled ‘Real-World Comparative Effectiveness Research and Related Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients Using Oral Anti-coagulants.’ The study aimed to compare the risk of major bleeding and stroke/systemic embolism events in patients with non-valvular atrial fibrillation (NVAF) who are new to oral anticoagulant treatments like warfarin, apixaban, dabigatran, or rivaroxaban. This research is significant as it provides insights into the real-world effectiveness and safety of these treatments, which can influence clinical decision-making and healthcare policies.
Intervention/Treatment: The study focused on four oral anticoagulants: Warfarin, Apixaban, Dabigatran, and Rivaroxaban. These medications are used to prevent blood clots in patients with NVAF, aiming to reduce the risk of stroke and systemic embolism.
Study Design: This was an observational study using a cohort model with a retrospective time perspective. The study did not involve any intervention allocation or masking, as it aimed to observe real-world outcomes in patients already receiving these treatments.
Study Timeline: The study began on June 1, 2016, and was first submitted on March 17, 2017. The last update was submitted on June 24, 2025. These dates are crucial as they mark the progression and updates of the study, reflecting its ongoing relevance and the timeliness of its findings.
Market Implications: The completion of this study could impact Bristol-Myers Squibb’s stock performance by providing valuable data on the safety and effectiveness of its anticoagulant, Apixaban. Positive outcomes may boost investor confidence and position the company favorably against competitors like Pfizer and Johnson & Johnson, which also produce anticoagulants.
The study is completed, and further details are available on the ClinicalTrials portal.